{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:24:17Z","timestamp":1794929057699,"version":"4.9.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.annonc.2025.05.007","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T19:14:17Z","timestamp":1747422857000},"page":"976-987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5708-2794","authenticated-orcid":false,"given":"J.N.","family":"Graff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Burotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2689-8958","authenticated-orcid":false,"given":"P.C.","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.W.","family":"Pook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Zurawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8106-9741","authenticated-orcid":false,"given":"R.","family":"Manneh Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.A.","family":"Bylow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Retz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Arranz Arija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0217-5261","authenticated-orcid":false,"given":"H.","family":"Gurney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Todenh\u00f6fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.W.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Todoric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1246-5601","authenticated-orcid":false,"given":"K.","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stenzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.annonc.2025.05.007_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.05.007_bib2","article-title":"NCCN clinical practice guidelines in oncology: prostate cancer, version 5.2024","year":"2024","journal-title":"National Comprehensive Cancer Network"},{"issue":"2","key":"10.1016\/j.annonc.2025.05.007_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.annonc.2025.05.007_bib4","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2014.02.056","article-title":"Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)","volume":"66","author":"Rathkopf","year":"2014","journal-title":"Eur Urol"},{"issue":"15","key":"10.1016\/j.annonc.2025.05.007_bib5","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.annonc.2025.05.007_bib6","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.annonc.2025.05.007_bib7","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1172\/JCI96268","article-title":"Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy","volume":"128","author":"Jayaprakash","year":"2018","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.annonc.2025.05.007_bib8","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1158\/1078-0432.CCR-07-5164","article-title":"Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing","volume":"14","author":"Sfanos","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.annonc.2025.05.007_bib9","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1158\/0008-5472.CAN-15-1965","article-title":"Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural killer cell antitumor activity","volume":"76","author":"Pasero","year":"2016","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.annonc.2025.05.007_bib10","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1158\/1078-0432.CCR-20-1981","article-title":"Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant prostate cancer: a phase I study","volume":"27","author":"Petrylak","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.annonc.2025.05.007_bib11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.05.007_bib12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.annonc.2025.05.007_bib13","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.ajpath.2018.02.014","article-title":"Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer","volume":"188","author":"Haffner","year":"2018","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/j.annonc.2025.05.007_bib14","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1158\/1078-0432.CCR-15-2042","article-title":"The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer","volume":"22","author":"Gevensleben","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2025.05.007_bib15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.18632\/oncotarget.2703","article-title":"PD-L1 is highly expressed in enzalutamide resistant prostate cancer","volume":"6","author":"Bishop","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.annonc.2025.05.007_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000642","article-title":"A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone","volume":"8","author":"Graff","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2025.05.007_bib17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41391-024-00865-5","article-title":"Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study","volume":"28","author":"Graff","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.annonc.2025.05.007_bib18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.euo.2023.10.008","article-title":"Pembrolizumab and enzalutamide in patients with abiraterone acetate-pretreated metastatic castration-resistant prostate cancer: cohort C of the phase 1b\/2 KEYNOTE-365 study","volume":"7","author":"Yu","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.05.007_bib19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","article-title":"Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial","volume":"28","author":"Powles","year":"2022","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.annonc.2025.05.007_bib20","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO-24-01283","article-title":"Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-921 trial.","volume":"43","author":"Petrylak","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.05.007_bib21","series-title":"Men with Metastatic Castration-resistant Prostate Cancer","article-title":"A Phase 3, Randomized, Double-blind Study of Nivolumab or Placebo in Combination with Docetaxel","year":"2019"},{"key":"10.1016\/j.annonc.2025.05.007_bib22","series-title":"Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer to Stop for Futility","year":"2023"},{"key":"10.1016\/j.annonc.2025.05.007_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108707","article-title":"The efficacy of PD-1\/PD-L1 blockade in cold cancers and future perspectives","volume":"226","author":"Majidpoor","year":"2021","journal-title":"Clin Immunol"},{"issue":"7647","key":"10.1016\/j.annonc.2025.05.007_bib24","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nature21676","article-title":"Effective combinatorial immunotherapy for castration-resistant prostate cancer","volume":"543","author":"Lu","year":"2017","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.annonc.2025.05.007_bib25","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.annonc.2024.09.004","article-title":"Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial","volume":"35","author":"Van Wilpe","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425001991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425001991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:06:13Z","timestamp":1774512373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425001991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0923753425001991"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.05.007","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates and The Author(s). Published by Elsevier Ltd. on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}